View Full-text Download PDF (308kb)

Background: The term “Ozempic face” has entered both medical and public discourse to describe facial hollowing, skin laxity, wrinkling, and age-amplifying soft-tissue changes observed after rapid weight loss associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. Although the phrase is now widely recognized, the scientific literature remains heterogeneous and is composed largely of reviews, commentaries, infodemiologic studies, surveys, case reports, and small interventional series. Methods: A comprehensive review of studies published between 2024 and 2026 in MEDLINE, PubMed, and Ovid was undertaken. Forty-four articles addressing semaglutide- and GLP-1RA-associated facial, skin, perioperative, psychosocial, ethical, and therapeutic issues were analyzed. Studies were classified according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence (March 2009). Results: The available literature suggests that “Ozempic face” is best understood not as a drug-specific facial disease, but as a clinically recognizable soft-tissue phenotype resulting from rapid or substantial weight loss, often superimposed on baseline intrinsic and extrinsic facial aging. Recurrent themes across the 44 studies included midfacial deflation, temporal hollowing, periorbital skeletonization, skin redundancy, worsened rhytides, and patient dissatisfaction despite successful metabolic outcomes. Public interest in both cosmetic weight loss and facial restoration rose sharply in parallel with widespread GLP-1RA adoption. The evidence base remains dominated by lower-level studies, but emerging reports describe potential roles for topical volumizers, biostimulatory injectables, hyaluronic acid fillers, radiofrequency-based tightening, ultrasound-associated peri-procedural regimens, and preventive aesthetic planning. Ethical concerns include off-label cosmetic prescribing, drug allocation, informed consent, body-image pressure, and the risk of stigmatizing effective obesity treatment. Conclusions: “Ozempic face” is a useful descriptive term, but it risks oversimplifying a multifactorial phenomenon driven by weight-loss velocity, magnitude of adipose depletion, age-related tissue reserve, skin quality, and patient expectations. Current evidence supports a multidisciplinary approach centered on anticipatory counseling, individualized facial assessment, conservative preventive strategies, and tailored restorative management. Higher-quality prospective studies with objective imaging, standardized outcome measures, and longer follow-up are needed to define incidence, risk factors, prevention, and treatment efficacy.

Keywords: semaglutide; glucagon-like peptide 1 receptor agonists; weight loss; face; skin aging; body image